Novo Nordisk’s weight loss drug, Wegovy, has officially launched in India, marking a significant advancement in obesity treatment. Administered once weekly via a pen device, Wegovy contains semaglutide, a compound that mimics a natural hormone regulating appetite and blood sugar.
With five dosage options and clinically proven benefits—10–15% average weight loss and reduced cardiovascular risks—Wegovy is a world-class solution for chronic weight management.
However, its pricing, starting at ₹17,345 per month and rising to ₹26,015 for higher doses, positions it as a premium product. In a country where obesity affects millions, often from lower-income groups, such high costs make the drug largely inaccessible.
This raises critical questions about healthcare equity and the affordability of advanced treatments. India faces an obesity epidemic, contributing to rising cases of diabetes, heart disease, and liver disorders. While Wegovy’s efficacy is not in doubt, its reach remains limited.
Its launch also intensifies competition in India’s anti-obesity drug market, where Eli Lilly’s Mounjaro offers a slightly cheaper alternative, yet still beyond the financial reach of most.
The arrival of Wegovy is a double-edged sword: it highlights scientific progress but also exposes the deep inequities in healthcare access. Addressing obesity requires not just advanced drugs but also prevention strategies, education, and affordable public health initiatives.
Without a broader, inclusive approach, such breakthroughs risk becoming tools for the privileged few, rather than catalysts for systemic change in India’s battle against obesity.
The fourth week in the Bigg Boss TV show began with a storm. Instead of…
Director Sukumar's assistants turned directors are trying to make a mark for themselves in Tollywood.…
